Share on StockTwits

Analysts at Deutsche Bank decreased their target price on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) from $115.00 to $70.00 in a research report issued to clients and investors on Wednesday, AmericanBankingNews.com reports. Deutsche Bank’s target price would suggest a potential upside of 58.51% from the company’s current price.

Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 26.31% on Wednesday, hitting $32.54. The stock had a trading volume of 5,014,852 shares. Aegerion Pharmaceuticals has a 1-year low of $40.16 and a 1-year high of $101.00. The stock’s 50-day moving average is $44.82 and its 200-day moving average is $61.45. The company’s market cap is $957.0 million.

Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.35) by $0.10. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. On average, analysts predict that Aegerion Pharmaceuticals will post $-0.36 earnings per share for the current fiscal year.

In other Aegerion Pharmaceuticals news, Insider Craig Fraser unloaded 2,250 shares of Aegerion Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $43.55, for a total transaction of $97,987.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at Cowen and Company downgraded shares of Aegerion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They now have a $36.00 price target on the stock, down previously from $85.00. Separately, analysts at FBR Capital Markets cut their price target on shares of Aegerion Pharmaceuticals from $111.00 to $107.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Aegerion Pharmaceuticals from $80.00 to $61.00 in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $81.88.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.